Full
Outline
To observe the clinical effect of Qili Qianxin Capsule（芪苈强心胶囊）combined with valsartan on senile patients with degenerative heart valvular disease complicated with heart failure.
A total of 168 elderly patients with degenerative heart disease combined with heart failure admitted from July 2022 to March 2024 were divided into groups by random number table method. All patients received conventional treatment, 84 patients in the valsartan group received valsartan capsule simultaneously, and 84 patients in the combination treatment group received Qili Qianxin Capsule combined with valsartan simultaneously. The data of two groups was observed：treatment efficacy, treatment adverse reactions, the cardiac ultrasound indicators before and after treatment, the changes in 6-minute walk test（6MWT）indicators, the levels of N-terminal pro B-type natriuretic peptide（NT-proBNP）, tumor necrosis factor-α（TNF-α）, homocysteine（HCY）and transforming growth factor-β1（TGF-β1）and Minnesota Living with Heart Failure Questionnaire（MLHFQ）scores.
The total effective rate of the combination treatment group and valsartan group was 96.43%（81/84）and 86.90%（73/84）, respectively, and the former was higher（P < 0.05）. The rate of adverse reactions was lower in the combination group and valsartan group（P > 0.05）. Left ventricular end diastolic dimension（LVEDD）and Left ventricular end systolic diameter（LVESD）, left ventricular ejection fractions（LVEF）and other echocardiographic indexes, 6MWT, the levels of NT-proBNP, TNF-α, HCY and TGF-β1 and MLHFQ scores before treatment in two groups were not significant（P > 0.05）. After treatment, the cardiac ultrasound indexes（LVEDD, LVESD, LVEF）, 6MWT, the levels of NT-proBNP, TNF-α, HCY and TGF-β1, MLHFQ scores and so on were improved in both groups. And these indexes in the combination treatment group were better than those in the valsartan group（P < 0.05）.
The combined treatment of Qili Qianxin Capsule and valsartan has good clinical effect in the elderly patients with degenerative heart valvular disease complicated with heart failure. This treatment regimen can improve the symptoms, cardiac function, tolerance and quality of life of patients, and has few adverse reactions, which is worthy of application.
97
14
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
